Document is current
Any future updates will be listed below
-
Authors
Brennan, Paul N. https://orcid.org/0000-0001-8368-1478
MacMillan, Mark https://orcid.org/0000-0001-9102-1680
Manship, Thomas
Moroni, Francesca
Glover, Alison
Troland, Debbie
MacPherson, Iain
Graham, Catriona
Aird, Rhona https://orcid.org/0000-0002-1014-8063
Semple, Scott I. K.
Morris, David M.
Fraser, Alasdair R. https://orcid.org/0000-0001-7822-650X
Pass, Chloe
McGowan, Neil W. A.
Turner, Marc L.
Manson, Lynn
Lachlan, Neil J.
Dillon, John F. https://orcid.org/0000-0002-2164-4476
Kilpatrick, Alastair M. https://orcid.org/0000-0002-4795-8799
Campbell, John D. M.
Fallowfield, Jonathan A. https://orcid.org/0000-0002-5741-1471
Forbes, Stuart J. https://orcid.org/0000-0003-3715-2561
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MR/M007588/1)
- License Information
-
More Information
Article History
Received: 5 June 2024
Accepted: 11 November 2024
First Online: 10 January 2025
Competing interests
: P.N.B. has received educational honoraria from Takeda and has served as a consultant to Resolution Therapeutics. I.M.P. has received speaker fees from Advanz Pharma. J.F.D. has received research grants and lecture honoraria from Merck Sharp & Dohme, AbbVie and Gilead. A.M.K. is a consultant to Resolution Therapeutics. J.D.M.C. is a founder of and adviser to Resolution Therapeutics. J.A.F. serves as a consultant or advisory board member for Stellaris, Kynos Therapeutics, Resolution Therapeutics, Ipsen, River 2 Renal Corp., Stimuliver, Global Clinical Trial Partners and Guidepoint and has received speaker fees from HistoIndex and research grant funding from GlaxoSmithKline, Intercept Pharmaceuticals and Genentech. S.J.F. is a founder of and adviser to Resolution Therapeutics and an adviser to Cytotheryx. The other authors declare no competing interests.
